Cells to prevent/treat relapse following allogeneic stem cell transplantation

被引：12
作者：
Dietz, Andrew C. [1 ,2 ]
Wayne, Alan S. [1 ,2 ]
机构：
[1] Childrens Hosp Los Angeles, Div Hematol Oncol & Blood & Marrow Transplantat, Childrens Ctr Canc & Blood Dis, Los Angeles, CA 90027 USA
[2] Univ Southern Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Los Angeles, CA USA
来源：
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM | 2017年
关键词：
CHIMERIC ANTIGEN RECEPTOR; 2ND INTERNATIONAL WORKSHOP; DONOR LYMPHOCYTE INFUSION; CAR-T-CELLS; B-CELL; HEMATOLOGICAL MALIGNANCIES; INFILTRATING LYMPHOCYTES; ADOPTIVE IMMUNOTHERAPY; KILLER-CELLS; CD19;
D O I：
10.1182/asheducation-2017.1.708
中图分类号：
G40 [教育学];
学科分类号：
040101 ; 120403 ;
摘要：
Relapse of cancer remains one of the primary causes of treatment failure and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). A multitude of approaches have been used in the management of posttransplant relapse. This review focuses on recent data with cellular therapies designed to treat or prevent posttransplant relapse of hematologic malignancies, although many of these therapeutic approaches also have applications to solid tumors and in the nontransplant setting. Currently available cell therapies include second transplant, natural killer cells, monocyte-derived dendritic cell vaccines, and lymphocytes via donor lymphocyte infusion, antigen-primed cytotoxic T lymphocytes, cytokine-induced killer cells, marrow-infiltrating lymphocytes, and chimeric antigen receptor T cells. These treatment options offer the prospect for improved relapse-free survival after HSCT.
引用
收藏
页码：708 / 715
页数：8
相关论文
共 51 条
  • [1] T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
    Ali, Syed Abbas
    Shi, Victoria
    Maric, Irina
    Wang, Michael
    Stroncek, David F.
    Rose, Jeremy J.
    Brudno, Jennifer N.
    Stetler-Stevenson, Maryalice
    Feldman, Steven A.
    Hansen, Brenna G.
    Fellowes, Vicki S.
    Hakim, Frances T.
    Gress, Ronald E.
    Kochenderfer, James N.
    [J]. BLOOD, 2016, 128 (13) : 1688 - 1700
  • [2] [Anonymous], FDA Approval Brings First Gene Therapy to the United States
  • [3] Current Status of Leukemia Cytotherapy - Exploitation with Immune Cells
    Bao, Haiyan
    Wu, Depei
    [J]. CURRENT STEM CELL RESEARCH & THERAPY, 2017, 12 (03) : 188 - 196
  • [4] Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose
    Bar, Merav
    Sandmaier, Brenda M.
    Inamoto, Yoshihiro
    Bruno, Benedetto
    Hari, Parameswaran
    Chauncey, Thomas
    Martin, Paul J.
    Storb, Rainer
    Maloney, David G.
    Storer, Barry
    Flowers, Mary E. D.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (06) : 949 - 957
  • [5] Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts
    Bleakley, Marie
    Heimfeld, Shelly
    Loeb, Keith R.
    Jones, Lori A.
    Chaney, Colette
    Seropian, Stuart
    Cooley, Ted A.
    Sommermeyer, Franziska
    Riddell, Stanley R.
    Shlomchik, Warren D.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2015, 125 (07) : 2677 - 2689
  • [6] Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
    Brudno, Jennifer N.
    Somerville, Robert P. T.
    Shi, Victoria
    Rose, Jeremy J.
    Halverson, David C.
    Fowler, Daniel H.
    Gea-Banacloche, Juan C.
    Pavletic, Steven Z.
    Hickstein, Dennis D.
    Lu, Tangying L.
    Feldman, Steven A.
    Iwamoto, Alexander T.
    Kurlander, Roger
    Maric, Irina
    Goy, Andre
    Hansen, Brenna G.
    Wilder, Jennifer S.
    Blacklock-Schuver, Bazetta
    Hakim, Frances T.
    Rosenberg, Steven A.
    Gress, Ronald E.
    Kochenderfer, James N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (10) : 1112 - +
  • [7] Transferred WT1-Reactive CD8+ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients
    Chapuis, Aude G.
    Ragnarsson, Gunnar B.
    Nguyen, Hieu N.
    Chaney, Colette N.
    Pufnock, Jeffrey S.
    Schmitt, Thomas M.
    Duerkopp, Natalie
    Roberts, Ilana M.
    Pogosov, Galina L.
    Ho, William Y.
    Ochsenreither, Sebastian
    Woelfl, Matthias
    Bar, Merav
    Radich, Jerald P.
    Yee, Cassian
    Greenberg, Philip D.
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (174)
  • [8] Alpha interferon augments the graft-versus-leukaemia effect of second stem cell transplants and donor lymphocyte infusions in high-risk paediatric leukaemias
    Cooper, Nichola
    Rao, Kanchan
    Goulden, Nick
    Amrolia, Persis
    Veys, Paul
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2012, 156 (04) : 550 - 552
  • [9] D'Souza AFC., Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT): CIBMTR Summary Slides
  • [10] Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation
    de Haar, Colin
    Plantinga, Maud
    Blokland, Nina J. G.
    van Til, Niek P.
    Flinsenberg, Thijs W. H.
    Van Tendeloo, Viggo F.
    Smits, Evelien L.
    Boon, Louis
    Spel, Lotte
    Boes, Marianne
    Boelens, Jaap Jan
    Nierkens, Stefan
    [J]. ONCOIMMUNOLOGY, 2015, 4 (11): : 1 - 11
123456